Of these patients, nearly two-thirds present with unresectable locally advanced or metastatic disease at initial diagnosis.[3] Since the discovery that epidermal growth factor receptor (EGFR)-sensitizing mutations are frequent oncogenic driver of NSCLC, many randomized trials were performed and demonstrated the benefit of EGFR tyrosine kinase inhibitors (TKI) over cytotoxic chemotherapy in patients with EGFR-sensitizing tumors [4-11]. Here, EGFR is linked to non-small cell lung carcinoma.